RG 6440
Alternative Names: RG-6440; RO-7496353; SOF-10Latest Information Update: 17 Jun 2025
At a glance
- Originator Chugai Pharmaceutical
- Developer Chugai Pharmaceutical; Genentech; Roche
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunostimulants; Transforming growth factor beta1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 25 Apr 2025 Adverse events and pharmacodynamics data from a pre-clinical study in Cancer presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
- 28 Jan 2025 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Recurrent, Second-line therapy or greater) in Japan (IV)
- 28 Nov 2024 No recent reports of development identified for phase-I development in Solid-tumours in USA (IV)